MiPet Easecto - summary of medicine characteristics

Summary of medicine characteristics - MiPet Easecto

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

MiPet Easecto 5 mg chewable tablets for dogs 1.3–2.5 kg MiPet Easecto 10 mg chewable tablets for dogs >2.5–5 kg

MiPet Easecto 20 mg chewable tablets for dogs >5–10 kg MiPet Easecto 40 mg chewable tablets for dogs >10–20 kg

MiPet Easecto 80 mg chewable tablets for dogs >20–40 kg MiPet Easecto 120 mg chewable tablets for dogs >40–60 kg

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substance:

MiPet Easecto chewable tablets	sarolaner (mg)
for dogs 1.3–2.5 kg	5
for dogs >2.5–5 kg	10
for dogs >5–10 kg	20
for dogs >10–20 kg	40
for dogs >20–40 kg	80
for dogs >40–60 kg	120

Excipients:

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Chewable tablets.

Mottled brown coloured, square shaped chewable tablets with rounded edges.

The number embossed on one side refers to the strength (mg) of the tablets: “5”, “10”, ”20”, “40”, “80” or “120”.

4. CLINICAL PARTICULARS4.1 Target species

Dogs

4.2 Indications for use, specifying the target species

For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus ). The veterinary medicinal product has immediate and persistent tick killing activity for at least 5 weeks.

For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis ). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for at least 5 weeks. The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

For the treatment of sarcoptic mange (Sarcoptes scabiei ).

For the treatment of ear mite infestations (Otodectes cynotis ).

For the treatment of demodicosis (Demodex canis ).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

4.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

4.4 Special warnings for each target species

Parasites need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious parasite-borne diseases cannot be excluded.

4.5 Special precautions for use

Special precautions for use in animals

In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after handling the product.

The accidental ingestion of the product may potentially result in adverse effects, such as transient excitatory neurological signs. To prevent children from accessing the product, only one chewable tablet at a time should be removed from the blister pack and only when required. The blister pack should then be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

4.6 Adverse reactions (frequency and seriousness)

Mild and transient gastrointestinal signs such as vomiting and diarrhoea, transient neurological disorders such as tremor, ataxia or convulsion and systemic disorders such as lethargy, anorexia/inappetence may occur in very rare cases. These signs typically resolve without treatment.

The frequency of adverse reactions is defined using the following convention:

– very common (more than 1 in 10 animals treated displaying adverse reaction(s))
– common (more than 1 but less than 10 animals in 100 animals treated)
– uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
– rare (more than 1 but less than 10 animals in 10,000 animals treated)
– very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects. Use only accordingly to the benefit-risk assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

None known.

During clinical field trials, no interactions between MiPet Easecto chewable tablets for dogs and routinely used veterinary medicinal products were observed.

In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated).

Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.

4.9 Amounts to be administered and administration route

For oral use.

Tablets can be administered with or without food.

The veterinary medicinal product should be administered at a dose of 2–4 mg/kg bodyweight in accordance with the following table:

Bodyweight (kg)	Tablet strength (mg sarolaner)	Number of tablets to be administered
1.3–2.5	5	One
>2.5–5	10	One
>5–10	20	One
>10–20	40	One
>20 –40	80	One
>40–60	120	One
>60	Appropriate combination of tablets

Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg.

MiPet Easecto tablets are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.

Treatment schedule:

For optimal control of tick and fleas infestations, the veterinary medicinal product should be administered at monthly intervals and continue throughout the flea and/or tick season based on local epidemiological situations.

For the treatment of ear mite infestations (Otodectes cynotis ) a single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis ) a single dose should be administered at monthly intervals for two consecutive months.

For the treatment of demodicosis (caused by Demodex canis ) the administration of a single dose once monthly for three consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In a margin of safety study, the veterinary medicinal product was administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum exposure dose of 4 mg/kg at 28 day intervals for 10 doses. No adverse effects were observed at the maximum exposure dose of 4 mg/kg. In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum exposure dose and convulsions at 5 times the maximum exposure dose. All dogs recovered without treatment.

Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose. No treatment-related clinical signs were observed.

4.11 Withdrawal period(s)

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Ectoparasiticides for systemic use.

ATC vet code: QP53BE03.

5.1 Pharmacodynamic properties

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors). Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines. Disruption of these receptors by sarolaner prevents the uptake of chloride ions by GABA and glutamate gated ion channels, thus resulting in increased nerve stimulation and death of the target parasite. Sarolaner exhibits higher functional potency to block insect/acarine receptors compared to mammalian receptors. Sarolaner does not interact with known insecticidal binding sites of nicotinic or other GABAergic insecticides such as neonicotinoids, fiproles, milbemycins, avermectins, and cyclodienes. Sarolaner is active against adult fleas (Ctenocephalides felis and Ctenocephalides canis ) as well as several tick species such as Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus , Rhipicephalus sanguineus and the mites Demodex canis , Otodectes cynotis and Sarcoptes scabiei.

For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after product administration. For ticks (I. ricinus ), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration. Ticks on the animal prior to administration are killed within 24 hours.

The veterinary medicinal product kills newly emerged fleas on the dog before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access.

5.2 Pharmacokinetic particulars

The bioavailability of sarolaner following oral dosing was high at >85%. Sarolaner was dose proportional in Beagle dogs when dosed from the intended use dose of 2–4 mg/kg, to 20 mg/kg. The prandial state of the dog does not significantly affect the extent of its absorption.

Sarolaner was determined to have low clearance (0.12 ml/min/kg) and a moderate volume of distribution (2.81 l/kg). Half-life was comparable for the intravenous and oral routes at 12 and 11 days, respectively. Plasma protein binding was determined in vitro and calculated at >99.9%.

A distribution study determined that 14C-sarolaner-related residues were widely distributed to the tissues. The depletion from tissues was consistent with the plasma half-life.

The primary route of elimination is biliary excretion of parent molecule, with elimination through the faeces.

6. PHARMACEUTICAL PARTICULARS6.1 List of excipients

Hypromellose acetate succinate, medium grade

Lactose monohydrate

Sodium starch glycolate

Silica, colloidal anhydrous

Magnesium stearate

Maize starch

Confectioner’s sugar

Glucose, liquid (81.5% solids)

Spray dried pork liver powder

Hydrolysed vegetable protein

Gelatin type A

Wheat germ

Calcium hydrogen phosphate anhydrous

6.2 Major incompatibilities

Not applicable.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.

6.4. Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

6.5 Nature and composition of immediate packaging

Aluminium foil/foil blister package.

One carton contains one blister of 3 tablets.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

7. MARKETING AUTHORISATION HOLDER

Zoetis Belgium SA

Rue Laid Burniat 1

1348 Louvain-la-Neuve

BELGIUM

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/17/220/001–006

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 31/01/2018.